




RealRate

PHARMACEUTICAL 2022

Endonovo Therapeutics INC
Rank 463 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Endonovo Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Endonovo Therapeutics INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Endonovo Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 217% points.

The company's Economic Capital Ratio, given in the ranking table, is 45%, being 230% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	95
Cost of Goods Sold	15
Intangible Assets	1,912
Liabilities, Current	17,702
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,285
Other Liabilities	80
Other Net Income	-878
Other Revenues	73
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	2,007
Liabilities	17,782
Expenses	2,300
Revenues	73
Stockholders Equity	-15,774
Net Income	-3,105
Comprehensive Net Income	-3,105
BaseVar	11,520
ECR before LimitedLiability	-379%
Economic Capital Ratio	45%